Matches in Wikidata for { <http://www.wikidata.org/entity/Q57579477> ?p ?o ?g. }
- Q57579477 description "article scientifique publié en 2014" @default.
- Q57579477 description "artículu científicu espublizáu en mayu de 2014" @default.
- Q57579477 description "im Mai 2014 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57579477 description "scientific article published on 14 May 2014" @default.
- Q57579477 description "wetenschappelijk artikel" @default.
- Q57579477 description "наукова стаття, опублікована в травні 2014" @default.
- Q57579477 name "Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact" @default.
- Q57579477 name "Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact" @default.
- Q57579477 type Item @default.
- Q57579477 label "Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact" @default.
- Q57579477 label "Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact" @default.
- Q57579477 prefLabel "Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact" @default.
- Q57579477 prefLabel "Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact" @default.
- Q57579477 P1433 Q57579477-BED74095-5692-463B-98BE-09C2912559C8 @default.
- Q57579477 P1476 Q57579477-67D4F62D-374E-4BE9-A724-E10C4129A027 @default.
- Q57579477 P2093 Q57579477-11AF1228-8019-4F43-849D-927125AA5C46 @default.
- Q57579477 P2093 Q57579477-152B6513-321A-4DFF-9987-3A94B380C7D4 @default.
- Q57579477 P2093 Q57579477-156977DA-0BCD-4A3F-8496-05B410EAAC0E @default.
- Q57579477 P2093 Q57579477-2024BE11-A161-49D9-888A-9735116ABF14 @default.
- Q57579477 P2093 Q57579477-28269DFD-E9F6-4B0B-8525-F5F3C01276D2 @default.
- Q57579477 P2093 Q57579477-2F358DE1-891F-49E4-8B57-7C74AE0F9F22 @default.
- Q57579477 P2093 Q57579477-35B8B8C2-5C6F-44BE-A6C8-694F316E02C8 @default.
- Q57579477 P2093 Q57579477-3F6F5F86-CA7B-465E-82DD-72DAAA3A5825 @default.
- Q57579477 P2093 Q57579477-64490AF2-CB31-44FD-9A30-729ED37AAECE @default.
- Q57579477 P2093 Q57579477-64F0D1A3-2BE4-4BF5-9BB8-5F7A6179C698 @default.
- Q57579477 P2093 Q57579477-75B751C0-5055-4959-A48B-802A0287495A @default.
- Q57579477 P2093 Q57579477-903107DA-5BFC-48FD-833C-524886685F1C @default.
- Q57579477 P2093 Q57579477-968D4A19-C487-4E64-8ED3-8886FF83414C @default.
- Q57579477 P2093 Q57579477-98487B4A-1449-48CF-A8E7-9ED076C1B986 @default.
- Q57579477 P2093 Q57579477-B237D890-FC5F-42D4-A70A-42C283F7EAFB @default.
- Q57579477 P2093 Q57579477-B672FE07-5B32-4822-8492-000B2D1C5CF6 @default.
- Q57579477 P2093 Q57579477-B6E1D8F3-83AC-47D4-AA69-654AD45186CE @default.
- Q57579477 P2093 Q57579477-B7176A30-87A4-4BE2-A9A3-52F4C1D14D67 @default.
- Q57579477 P2093 Q57579477-BFA202FB-7A41-40E7-B45A-ABAC92E17578 @default.
- Q57579477 P2093 Q57579477-C76CD7D6-A4B6-4345-A0DA-79F5F1D8D412 @default.
- Q57579477 P2860 Q57579477-0052E7E4-3AE9-47EB-98EB-5C6B7D2F927C @default.
- Q57579477 P2860 Q57579477-226A331A-076A-4ED9-9CA5-F65B6B5D25ED @default.
- Q57579477 P2860 Q57579477-2319769F-AC85-4B15-B7D2-5F5A50054291 @default.
- Q57579477 P2860 Q57579477-2EF8BD7F-5484-45CE-8ED3-19AD36F93E1A @default.
- Q57579477 P2860 Q57579477-3D4EF729-9ED9-47E1-BEC5-91BDF02C0A6C @default.
- Q57579477 P2860 Q57579477-588A7739-2F50-4DA8-8048-17823C8AC6FC @default.
- Q57579477 P2860 Q57579477-603EB00A-EC0A-4947-B213-282E6486B179 @default.
- Q57579477 P2860 Q57579477-83EBCBDD-C165-44D4-9835-6443F1977968 @default.
- Q57579477 P2860 Q57579477-8DEF79DC-E2BB-415B-881A-492849B411A1 @default.
- Q57579477 P2860 Q57579477-90A91A55-C41E-4BB7-96AD-52185C64DA8E @default.
- Q57579477 P2860 Q57579477-9E72292C-39FF-4E28-A096-7E8BA717DA17 @default.
- Q57579477 P2860 Q57579477-AAAE6EAD-07C7-4A5E-B292-515ACAD1991A @default.
- Q57579477 P2860 Q57579477-B855E4F5-45A2-4D44-98A3-D1D7B0D7A56B @default.
- Q57579477 P2860 Q57579477-B94D8035-BC8C-45EA-BBE2-ECC471283C2D @default.
- Q57579477 P2860 Q57579477-BAECC496-9056-4710-ABAE-F9463AC3C34C @default.
- Q57579477 P2860 Q57579477-DA4C7199-0549-4190-A9FE-70504CB22B4F @default.
- Q57579477 P2860 Q57579477-E478AFB8-F2C4-4A3E-B69D-385170FF0F91 @default.
- Q57579477 P2860 Q57579477-E52A478B-62F8-4E4E-8D28-9C4994E92424 @default.
- Q57579477 P2860 Q57579477-E9341867-8B10-448D-BAF0-EB625A6482F9 @default.
- Q57579477 P2860 Q57579477-F1DFB747-B2D0-453D-BD8E-1639ABEE009F @default.
- Q57579477 P2860 Q57579477-F730E98A-082F-44BB-9FD0-F7CF3190C3E6 @default.
- Q57579477 P2860 Q57579477-FA35CFD0-AA93-40F7-923C-3117C18FD783 @default.
- Q57579477 P2860 Q57579477-FA3A3A8B-D629-4664-8EDE-A0E8371C8303 @default.
- Q57579477 P304 Q57579477-70FE7439-7366-4833-ABCC-213FAB85BA23 @default.
- Q57579477 P31 Q57579477-DA58B2F2-D90F-458A-99F4-C941017916C0 @default.
- Q57579477 P356 Q57579477-34D9BFA6-E808-4A9B-90B6-FB3EC9A4EDE4 @default.
- Q57579477 P433 Q57579477-2675E858-AF9F-426B-A0CD-4A3C17952ACE @default.
- Q57579477 P478 Q57579477-86C879AA-B0E9-47D1-B885-0DFFAF26A7B4 @default.
- Q57579477 P50 Q57579477-0EA0D62D-FB09-4E31-AAC8-2C72B29C6A28 @default.
- Q57579477 P50 Q57579477-18851AB2-80ED-4254-9D7B-006BC417295A @default.
- Q57579477 P50 Q57579477-71DBDD61-5F59-457B-8911-66F50E2FB1A9 @default.
- Q57579477 P50 Q57579477-836882C4-558E-4068-8F95-E60C83ACF3B5 @default.
- Q57579477 P50 Q57579477-931D09C3-78AD-4499-9816-E096C5498B53 @default.
- Q57579477 P50 Q57579477-D0453CE5-C747-4B84-91B4-7BAD59E45218 @default.
- Q57579477 P577 Q57579477-890F07A6-7FFD-46C5-B613-13812947906A @default.
- Q57579477 P698 Q57579477-564B80EB-F6A6-47F7-9A65-E689861E63F7 @default.
- Q57579477 P921 Q57579477-082A4D71-AAF1-4C98-BC9A-5A4FE29E11A7 @default.
- Q57579477 P921 Q57579477-DABF9F5E-C9B7-4C00-83BB-CA8A7F544025 @default.
- Q57579477 P356 MDU183 @default.
- Q57579477 P698 24827135 @default.
- Q57579477 P1433 Q326122 @default.
- Q57579477 P1476 "Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact" @default.
- Q57579477 P2093 "A Desrichard" @default.
- Q57579477 P2093 "A M Forest" @default.
- Q57579477 P2093 "B Weber" @default.
- Q57579477 P2093 "C Jouannaud" @default.
- Q57579477 P2093 "F Kwiatkowski" @default.
- Q57579477 P2093 "F Penault-Llorca" @default.
- Q57579477 P2093 "I Van Praagh" @default.
- Q57579477 P2093 "J M Nabholtz" @default.
- Q57579477 P2093 "K E Benmammar" @default.
- Q57579477 P2093 "M A Mouret-Reynier" @default.
- Q57579477 P2093 "M M Dauplat" @default.
- Q57579477 P2093 "M R K Bahadoor" @default.
- Q57579477 P2093 "N Chalabi" @default.
- Q57579477 P2093 "N Radosevic-Robin" @default.
- Q57579477 P2093 "N Uhrhammer" @default.
- Q57579477 P2093 "P Chollet" @default.
- Q57579477 P2093 "P Dubray-Longeras" @default.
- Q57579477 P2093 "S Guiu" @default.
- Q57579477 P2093 "S Kullab" @default.
- Q57579477 P2093 "T Petit" @default.
- Q57579477 P2860 Q28299546 @default.
- Q57579477 P2860 Q34774874 @default.
- Q57579477 P2860 Q35889643 @default.